Am J Psychiatry 161:1822-1828, October 2004
© 2004 American Psychiatric Association
Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
Lawrence E. Adler,
Ann Olincy,
Ellen M. Cawthra,
Kara A. McRae,
Josette G. Harris,
Herbert T. Nagamoto,
Merilyne C. Waldo,
Mei-Hua Hall,
Amanda Bowles,
Laurie Woodward,
Randal G. Ross, and
Robert Freedman
OBJECTIVE: Sensory gating deficits found in schizophrenia can be assessed by using a paired auditory stimulus paradigm to measure auditory evoked response. The ratio of the P50 response amplitude of the second or test stimulus to that of the first or conditioning stimulus is expressed as a percentage. Normal subjects generally suppress the second response and typically have ratios of less than 40%. Subjects with schizophrenia and half their first-degree relatives have deficits in sensory gating, with P50 ratios that are generally greater than 50%. Treatment with typical neuroleptics does not reverse this deficit. However, previous studies have shown that treatment with clozapine, an atypical neuroleptic, ameliorates this deficit in clinically responsive patients. This study sought to determine whether other atypical neuroleptics improve P50 ratios. METHOD: P50 evoked potential recordings were obtained from 132 patients with schizophrenia and 177 healthy comparison subjects. Eighty-eight patients were being treated with atypical neuroleptics (clozapine [N=26], olanzapine [N=31], risperidone [N=22], and quetiapine [N=9]). Thirty-four patients were taking typical neuroleptics, and 10 were unmedicated. RESULTS: Healthy subjects exhibited P50 suppression that was significantly better than the schizophrenia patients receiving typical neuroleptics (mean=19.8% [SD=21.0%] versus 110.1% [SD=87.9%]). Patients receiving atypical neuroleptics had a mean P50 ratio that fell between these two means (mean=70.4%, SD=53.7%). When patients treated with different atypical neuroleptics were compared, only the clozapine group had mean P50 ratios that were in the normal range. All other groups exhibited auditory P50 response inhibition that was significantly poorer than that of the healthy subjects. CONCLUSIONS: Improvement in P50 gating appears to be greatest in patients treated with clozapine.
This article has been cited by other articles:
|
|
|
|
 
G. K. Thaker
Neurophysiological Endophenotypes Across Bipolar and Schizophrenia Psychosis
Schizophr Bull,
July 1, 2008;
34(4):
760 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. J Daskalakis, B. K Christensen, P. B Fitzgerald, B. Moller, S. I Fountain, and R. Chen
Increased cortical inhibition in persons with schizophrenia treated with clozapine
J Psychopharmacol,
March 1, 2008;
22(2):
203 - 209.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. A. Greenwood, D. L. Braff, G. A. Light, K. S. Cadenhead, M. E. Calkins, D. J. Dobie, R. Freedman, M. F. Green, R. E. Gur, R. C. Gur, et al.
Initial Heritability Analyses of Endophenotypic Measures for Schizophrenia: The Consortium on the Genetics of Schizophrenia
Arch Gen Psychiatry,
November 1, 2007;
64(11):
1242 - 1250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. de Wilde, L. J. Bour, P. M. Dingemans, J. H. T. M. Koelman, and D. H. Linszen
Failure to Find P50 Suppression Deficits in Young First-Episode Patients With Schizophrenia and Clinically Unaffected Siblings
Schizophr Bull,
November 1, 2007;
33(6):
1319 - 1323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Schizophr Bull,
September 1, 2007;
33(5):
1120 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Hall, F. Rijsdijk, M. Picchioni, K. Schulze, U. Ettinger, T. Toulopoulou, E. Bramon, R. M. Murray, and P. Sham
Substantial Shared Genetic Influences on Schizophrenia and Event-Related Potentials
Am J Psychiatry,
May 1, 2007;
164(5):
804 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Williams and J. Foulds
Successful Tobacco Dependence Treatment in Schizophrenia
Am J Psychiatry,
February 1, 2007;
164(2):
222 - 227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Hong, A. Summerfelt, I. Wonodi, H. Adami, R. W. Buchanan, and G. K. Thaker
Independent Domains of Inhibitory Gating in Schizophrenia and the Effect of Stimulus Interval
Am J Psychiatry,
January 1, 2007;
164(1):
61 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. I. Turetsky, M. E. Calkins, G. A. Light, A. Olincy, A. D. Radant, and N. R. Swerdlow
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Schizophr Bull,
January 1, 2007;
33(1):
69 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Potter, A. Summerfelt, J. Gold, and R. W. Buchanan
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Schizophr Bull,
October 1, 2006;
32(4):
692 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Olincy, J. G. Harris, L. L. Johnson, V. Pender, S. Kongs, D. Allensworth, J. Ellis, G. O. Zerbe, S. Leonard, K. E. Stevens, et al.
Proof-of-Concept Trial of an {alpha}7 Nicotinic Agonist in Schizophrenia.
Arch Gen Psychiatry,
June 1, 2006;
63(6):
630 - 638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Percaccio, N. D. Engineer, A. L. Pruette, P. K. Pandya, R. Moucha, D. L. Rathbun, and M. P. Kilgard
Environmental Enrichment Increases Paired-Pulse Depression in Rat Auditory Cortex
J Neurophysiol,
November 1, 2005;
94(5):
3590 - 3600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J Hagan and D. N C Jones
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia
Schizophr Bull,
October 1, 2005;
31(4):
830 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Adler, E. M. Cawthra, K. A. Donovan, J. G. Harris, H. T. Nagamoto, A. Olincy, and M. C. Waldo
Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients
Am J Psychiatry,
February 1, 2005;
162(2):
386 - 388.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
